The 1st conference of the ARCA Global network aims to advance a global consortium for translational studies in autosomal-recessive ataxias (ARCAs), ARCA Global. ARCA Global is a dynamic, collaborative translational research initiative ultimately aiming to prepare and conduct harmonized multi-center treatment trials in genetically stratified ARCAs, thus allowing to translate the recent progress in ARCA genetics directly into stringent targeted treatment trials. It will integrate all main stakeholder groups including basic and clinician scientists, industry, and patient organizations.
ViewJoin us at the Parker Hotel in Palm Springs, California, to meet colleagues, share ideas, and make new connections in the pursuit of therapeutics for Huntington's disease.
ViewOver the course of four stimulating days of in-depth discussions in 20 different conferences, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including: Site Selection and Management, Patient Engagement, Recruitment and Retention, Protocol Optimization, Feasibility, Data Strategy and Analytics, Sensors and Wearables, Artificial Intelligence, Clinical Biomarker Strategy, Precision Medicine, Clinical Biomarkers, and an all new track on Medical Device Clinical Trial Operations and Regulations.
The show is brought to you by the team at Shares Magazine, in partnership with Cenkos Securities. The Growth and Innovation Forum connects top experts, who will share their in-depth knowledge of investing and meet directors from fast-growing and technology led London listed companies.
For 5 years, the LSX World Congress has been bringing together the executives that matter to the future of healthcare and life science business strategy, investment, partnering, deal making and commercialisation.
LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life science giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.
The industry’s c-suite will be joined by the sector’s most active investors, pharma and healthtech BD&L teams, key stakeholders and top tier service companies who are moving the sector forward.
HAI 2020 will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily spring from brief presentations by active investigators who will report on unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
ViewThe program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover, there are panels on innovation in NeuroTech covering banking, device, diagnostics and software. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma, biotech and medtech companies.
The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
View129-136 of 155 results